Research team affirms useful blood biomarker for group of brain disorders in new study

A test of protein in the blood is receiving further support as a biomarker for patients diagnosed with frontotemporal dementia (FTD), a group of brain disorders with few treatment options. These disorders are characterized by changes in behavior, cognition, language or movement.
A test of protein in the blood is receiving further support as a biomarker for patients diagnosed with frontotemporal dementia (FTD), a group of brain disorders with few treatment options. These disorders are characterized by changes in behavior, cognition, language or movement.